Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4+ T cell activation and HIV-1 latency reversal

Nanotechnology approaches to eradicating HIV reservoirs

(2018) Shijie Cao et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Optimization and comparison of CD4-targeting lipid-polymer hybrid nanoparticles using different binding ligands

(2018) Shijie Cao et al.   JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A

Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells

(2018) Shijie Cao et al.   Nanomedicine-Nanotechnology Biology and Medicine

Lymph node targeting strategies to improve vaccination efficacy

(2017) Hao Jiang et al.   JOURNAL OF CONTROLLED RELEASE

Defining total-body AIDS-virus burden with implications for curative strategies

(2017) Jacob D Estes et al.   NATURE MEDICINE

Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells

(2016) Lachlan R. Gray et al.   JOURNAL OF NEUROVIROLOGY

Persistent HIV-1 replication maintains the tissue reservoir during therapy

(2016) Ramon Lorenzo-Redondo et al.   NATURE

Latency reversal and viral clearance to cure HIV-1

(2016) D. M. Margolis et al.   SCIENCE

HIV-1 Reservoirs During Suppressive Therapy

(2016) Kirston Barton et al.   TRENDS IN MICROBIOLOGY

Shocking HIV out of hiding

(2016) Thomas A. Rasmussen et al.   Current Opinion in HIV and AIDS

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

(2016) Héloïse M. Delagrèverie et al.   Open Forum Infectious Diseases

Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates

(2015) Jennifer P. Freeling et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Sustained-release nanoART formulation for the treatment of neuroAIDS

(2015) Rahul Jayant et al.   International Journal of Nanomedicine

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

(2015) Amanda M. Crooks et al.   JOURNAL OF INFECTIOUS DISEASES

PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread

(2015) Xiaolong Tang et al.   Nanoscale Research Letters

Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications

(2015) Biswajit Das et al.   VIROLOGY

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

(2015) Gilles Darcis et al.   PLoS Pathogens

Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

(2015) Guochun Jiang et al.   PLoS Pathogens

PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread

(2015) Xiaolong Tang et al.   Nanoscale Research Letters

Ingenol Mebutate: A Promising Treatment for Actinic Keratoses and Nonmelanoma Skin Cancers

(2015) Aditya K. Gupta et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Dose-Response Analysis Using R

(2015) Christian Ritz et al.   PLoS One

Bioengineered Vaults: Self-Assembling Protein Shell–Lipophilic Core Nanoparticles for Drug Delivery

(2014) Daniel C. Buehler et al.   ACS Nano

Quantitative Evaluation and Optimization of Co-drugging to Improve Anti-HIV Latency Therapy

(2014) Victor C. Wong et al.   Cellular and Molecular Bioengineering

Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway

(2014) J Park et al.   Mucosal Immunology

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

(2014) Courtney V. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence

(2014) J. P. Freeling et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunologic strategies for HIV-1 remission and eradication

(2014) D. H. Barouch et al.   SCIENCE

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo

(2013) E. J. Beans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Redefining the Viral Reservoirs that Prevent HIV-1 Eradication

(2012) Evelyn Eisele et al.   IMMUNITY

Activation of Latent HIV Using Drug-Loaded Nanoparticles

(2011) Michael Kovochich et al.   PLoS One

Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates

(2009) M. Di Mascio et al.   BLOOD

Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug

(2008) Andrea Brioschi et al.   MOLECULES